Lexicon Pharmaceuticals LXRX Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's business segments — net loss?
- Lexicon Pharmaceuticals (LXRX) reported business segments — net loss of -$1.04M in Q1 2026.
- How has Lexicon Pharmaceuticals's business segments — net loss changed year-over-year?
- Lexicon Pharmaceuticals's business segments — net loss increased by 95.9% year-over-year, from -$25.3M to -$1.04M.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — net loss?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — net loss has grown at a -21.0% compound annual growth rate (CAGR), from -$101.94M to -$50.34M.
- What does business segments — net loss mean?
- This metric measures the bottom-line financial performance of a specific business segment after accounting for all associated revenues, operating expenses, and non-operating costs. It indicates the extent to which a segment is currently consuming capital rather than generating profit, which is common in research-intensive biopharmaceutical development phases. A reduction in this loss over time is a key indicator of improved operational efficiency or successful commercialization progress.